The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being developed
as therapeutics and are a major contributor to neutralizing antibody responses elicited …

The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-mediated
immunity. To facilitate prospective surveillance for such evolution, we map how …

Following its emergence in late 2019, the spread of SARS-CoV-2 1 , 2 has been tracked by
phylogenetic analysis of viral genome sequences in unprecedented detail 3 , 4 – 5 . …

The development of vaccines against SARS-CoV-2 would be greatly facilitated by the
identification of immunological correlates of protection in humans. However, to date, studies on …

SARS-CoV-2 enters cells using its Spike protein, which is also the main target of
neutralizing antibodies. Therefore, assays to measure how antibodies and sera affect Spike-mediated …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with mutations in key antibody epitopes has raised concerns that antigenic evolution could …

Most individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
develop neutralizing antibodies that target the viral spike protein. In this study, we …

There is intense interest in antibody immunity to coronaviruses. However, it is unknown if
coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this …

A major challenge in understanding SARS-CoV-2 evolution is interpreting the antigenic and
functional effects of emerging mutations in the viral spike protein. Here, we describe a deep …